Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection

Rodolfo Miglioli Badial, MSa, Marina Carrara Dias, MSa, Bruna Stuqui, PhDa,
Patricia Pereira dos Santos Melli, MD9, Silvana Maria Quintana, MDc, Caroline Measso do Bonfim, PhDa,
José Antônio Cordeiro, PhDd, Tatiana Rabachini, PhDe, Marilia de Freitas Calmon, PhDa,
Paola Jocelan Scarin Provazzi, PhDe, Paula Rahal, PhDa,
Rodolfo Miglioli Badial, MSa, Marina Carrara Dias, MSa, Bruna Stuqui, PhDa,
Patricia Pereira dos Santos Melli, MD9, Silvana Maria Quintana, MDc, Caroline Measso do Bonfim, PhDa,
José Antônio Cordeiro, PhDd, Tatiana Rabachini, PhDe, Marilia de Freitas Calmon, PhDa,
Paola Jocelan Scarin Provazzi, PhDe, Paula Rahal, PhDa,

Abstract
HPV have been identified as high-risk and low-risk, depending on their association with the development of cancer. HPV infections can be facilitated by co-infection with HIV. Here, we investigated HPV prevalence and genotypes and the risk factors affecting HPV/HIV co-infection. Forty HIV-positive patients had 80 cervical swab samples collected in 2 consecutive years. Polymerase chain reaction and DNA direct sequencing were used to perform HPV genotyping. Statistical analyses were performed regarding risk factors for HPV/HIV co-infection and the occurrence of cervical lesions. HPV DNA was detected in 59 samples (73.75%), and high-risk HPV types were predominant (59.3%). The most prevalent type was HPV16 (17%), followed by HPV16 (15.3%). Patient age did not affect the risk of cervical cancer (P = .84) or HPV prevalence in different years (P = .25/P = .63). CD4 count also did not affect the risk for cervical lesions in the tested samples (P = .15/P = .28). Although the HIV viral load was not correlated with an increase in cervical lesion detection in the first group of analyzed samples (P = .12), it did affect cervical cancer risk in the group of samples analyzed in the following year (P = .045). HIV-infected patients presented a high prevalence of HPV co-infection, and HPV16 and HPV56 were the most prevalent genotypes. Considering this, it is possible that immunodeficiency can contribute to increased susceptibility to HPV56 infection in HIV-infected patients. The association between HIV viral load and the lesions also confirmed the importance of monitoring HIV/HPV co-infected patients with high HIV viral loads.

Abbreviations: ART = antiretroviral therapy, bp = base pair, CD4 = CD4 molecule, CIN = cervical intraepithelial neoplasia, CIN I = cervical intraepithelial neoplasia low grade, CIN II = cervical intraepithelial neoplasia moderate grade, CIN III = cervical intraepithelial neoplasia high grade to carcinoma in situ, DNA = deoxyribonucleic acid, E6 = HPV E6 protein, E7 = HPV E7 protein, HIV = human immunodeficiency virus, HPV = human papillomavirus, HR = high-risk, kb = kilobase, LA = low-risk, NESTED-PCR = nested polymerase chain reaction, p53 = p53 protein, Pap = papanicolaou, PCR = polymerase chain reaction, pRb = retinoblastoma protein, SIL = squamous intraepithelial lesion, SD = standard deviation, VL = viral load.

Keywords: cervical lesions, HIV, HIV co-infection, HPV

1. Introduction
Papillomaviruses are circular and double-stranded deoxyribonucleic acid (DNA) viruses with a genome of approximately 8 kilobases (kb).[1] These viruses are also non-enveloped and can induce squamous epithelial tumors (warts and papillomas) in many different anatomical sites.[1] The human papillomavirus (HPV) has over 200 identified viral types and can be classified into 2 groups, high-risk and low-risk, depending on their association with cancer development.[2] The most common high-risk (HR) HPV types are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, and they are associated with moderate and high-grade cervical lesions and cervical cancers.[1] HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases.[4] The most common low-risk (LR) HPV types are 6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and 81, and they can cause low-grade cervical lesions, such as genital warts (condyloma) and benign cervical lesions, and are rarely detected in malignant neoplasms.[1,5]

High-risk HPV types, once integrated into the host genome, exert their oncogenic effects primarily through the continuous expression of the HPV E6 protein (E6) and the HPV E7 protein (E7).[1,3] These oncoproteins play a central role in HPV-dependent malignant transformation and are expressed in cervical cancer.[1,6] Both E6 and E7 proteins target tumor suppressor proteins, such as the p53 protein (p53) and the retinoblastoma...
protein (pRB), and are able to induce cell proliferation, inhibit apoptosis, and promote genome instability and evasion of the innate immune system.[7,8]

High-risk HPV infection plays a crucial role in the development of cervical cancer, which is the third most frequent gynecological malignancy in women worldwide.[9] It has been estimated that approximately 529,800 new cases and 275,100 deaths occur each year in the world.[10] In Brazil, it is estimated that there are approximately 16,340 new cases and 5430 deaths in 1 year.[10]

Invasive cervical carcinoma is preceded by precursor lesions that are characterized by cellular maturation disorders, layering, and atypical cores. The precursor lesions can be histologically classified as cervical intraepithelial neoplasia (CIN) with 3 grades (low grade - CIN I; moderate grade - CIN II; and high grade to carcinoma in situ - CIN III), or they can be cytologically classified as squamous intraepithelial lesions (SIL).[1] Due to these well-defined premalignant stages, cervical cancer is particularly amenable to screening. The classical method of screening is based on the cytological evaluation of smears.[11]

Women infected with human immunodeficiency virus (HIV) are at greater risk for HPV infection and persistence, increasing the risk of abnormalities in the cervical cells and invasive cervical cancer.[12] HIV infection leads to a decline in both the number and function of CD4+ T cells and this can lead to a high rate of infection with HPV, which reduces the chance of their spontaneous elimination.[12]

HPV DNA detection tests can be implemented as an auxiliary tool, in combination with cervical cytology, to improve the management of patients at risk for cervical disease,[13] primarily in HIV-positive patients. HPV genotyping is other important test that can contribute to the prevention of invasive cervical cancer[14] and is essential to the better understanding of the high-risk types of HPV for the introduction of an effective immunization program. This information is also necessary to evaluate the benefit of the vaccines, especially the nonvalent vaccine that can prevent against infection with the 4 HPV types present in the quadrivalent vaccine (HPV6, 11, 16, and 18) and 5 more types (HPV31, 36, 45, 52, and 58), and this can enhance the prevention of cervical cancer in the population.[15]

The objective of this study was to detect and genotype HPV in cervical swab samples from HIV-infected women, as well to investigate the risk factors associated with HPV/HIV co-infection.

2. Methods

2.1. Clinical samples

The project was approved, and ethical permission was obtained from the Research Committee of the Department of Gynecology and Obstetrics of the Ribeirão Preto Medical School, University of São Paulo and by the Ethics Committee at the Research Hospital (HC-FMRP/USP). Project 233 was approved on November 15, 2009.

A prospective study evaluated 80 cervical swab samples from 40 female patients diagnosed with HIV infection. The samples had been previously collected during 2 periods: from 2010 to 2011 (collection I) and from 2011 to 2012 (collection II). For the patients’ follow-up, the women were evaluated at the Ambulatory Unit of Infectious Diseases of Gynecology and Obstetrics (AMIGO) of the Clinical Hospital (HC-FMRP/USP) located in the city of Ribeirão Preto, São Paulo State, Brazil. To determine their HIV status and/or the presence of HPV-related lesions, Pap test procedures were performed, and colposcopies and biopsies were performed when lesions were present.

HPV infection type was classified as clinical (in case of warts), subclinical (in cases where colposcopic lesions became evident), or HPV-positive (if only polymerase chain reaction (PCR) positive).

The inclusion criteria were as follows:

1. The subject must be an HIV-infected woman, as defined by the ELISA test, undergoing antiretroviral treatment at the Ambulatory Unit of Infectious Diseases of Gynecology and Obstetrics (AMIGO) of the Clinical Hospital (HC-FMRP/USP).
2. The subject must have read and signed the informed consent form. Clinical pathological data from patients included in the study were collected from medical records.

Cervical samples (with 2.0 mL of saline solution) were collected from all women and subjected to DNA extraction according to the phenol method[16] and tested for HPV by nested polymerase chain reaction (NESTED-PCR).

2.2. Nested polymerase chain reaction (NESTED-PCR)

Polymerase chain reaction (PCR) was used to amplify the DNA of the human papillomavirus present in the cervical swab samples. Degenerated oligonucleotides PGMY09 (5-CGT CCM ARR GGA WAC TAGTC-3) and PGMY11 (5-GCM CAG GGW CAT AAY AAT GG-3) were used to detect viral DNA. The amplification products were used in a nested PCR with the oligonucleotides GPS+ (5-TTTGTTACTGTTGAGATACATAC-3) and GP6+ (5- CTTTATCTAATGTCATAAAAAA-3), which amplify a 150-bp sequence internal to the fragment produced by the pair of oligonucleotides PGMY09/PGMY11.[17] The products of the amplifications were run electrophoretically on a 1% agarose gel.

2.3. Sequencing

Sequencing was carried out according to the Sanger technique,[18] using the BigDye terminator kit (Applied Biosystems/Life Technologies, Foster City, CA, USA). A sequence of 34 bases downstream of the GPS+ binding site was used for accurate genotyping of HPV types.[19] The generated sequences were quality assessed by use of PHRED/PHRAP/CONSED software and were then aligned and checked for similarity with the sequences deposited in GenBank using the BLAST tool - Basic Local Alignment System,[20] BioEdit – Biological Sequence Alignment Editor[21] and Blat - Human Genome Search.[22]

2.4. Statistical analysis

Statistical tests were used depending on the nature of the variables. Qualitative variables were analyzed by Pearson’s test, and the means of quantitative variables were compared by t-test or, when recommended, by Fisher’s test. The Pearson coefficient was calculated to search for correlations between HPV and cervical lesions, antiretroviral therapy (ART) and cervical lesions, age and cervical lesions, CD4 count and cervical lesions and HIV viral load (VL) and cervical lesions. P-value < .05 was considered not significant.

3. Results

A total of 80 cervical samples, collected in 2 consecutive years from 40 HIV-positive patients, were enrolled in the study. HPV DNA was identified in 59 samples (73.75%), of which 34 samples (57.62%) were high-risk HPV-positive (19 in collection I and 15 in collection II) and 25 (40.6%) were low-risk HPV-positive (11 in collection I and 14 in collection II) (Table 1). The...
HPV-positive rate among analyzed patients was 85% (34 patients), of which 25 (73.53%) presented HPV in both collected samples, and 9 (26.5%) presented HPV in only one of the collected samples. A total of 6 patients (15%) did not present HPV in either collected sample. A total of 21 patients were infected with high-risk HPV, and 17 were infected with low-risk HPV in at least one of the collected samples. Twelve patients (30%) presented high-risk HPV, and 7 patients (17.5%) presented low-risk HPV in both collected samples (Table 2).

HPV genotyping was performed, and HPV56 was the predominant genotype in cervical swab samples, corresponding to 17% (10/59) of the identified types, followed by HPV16, which was found in 15.3% (9/59) of the cases. HPV81 was detected in 10.2% (6/59), HPV62 in 6.8% (4/59), HPV83 in 3.4% (2/59) and HPV types 6, 18, 26, 33, 52, 59, 72, 74, 90, and 114 occurred in 1.7% (1/59) of the sequenced samples (Table 2).

Cervical lesions were detected in 9 patients (22.5% of the cases) in the first collection. From these, 7 patients presented only CIN I, while 1 patient presented CIN II, and 1 patient was diagnosed with CIN II and CIN III (Table 2). In the second visit collection, cervical lesions were detected in 11 patients (27.5%). From these, eight were diagnosed as CIN I, 1 as CIN I and CIN II and 2 as CIN I and CIN III (Table 2).

The patients’ demographic characteristics and associated risk factors were also assessed. The mean age of patients with lesions was 39.9 years (standard deviation (SD) = 8.92), while in patients with no lesions, it was 40.6 years (SD = 11.5). The mean age of

---

### Table 1

Prevalence of high-risk HPV and low-risk HPV types in cervical swab samples from HIV-infected women.

|                | Collect I | Collect II | Total Samples |
|----------------|-----------|------------|---------------|
| High-risk HPV  | 19/30 (63.33%) | 15/29 (51.74%) | 34/59 (57.62%) |
| Low-risk HPV   | 11/30 (36.67%) | 14/29 (48.26%) | 25/59 (42.38%) |

HPV = Human papillomavirus.

### Table 2

HPV positivity and HPV types in HIV-infected women.

| Patients | Type | HR/LR | CD4 mm$^3$ | Lesions | Collect I | Type | HR/LR | CD4 mm$^3$ | Lesions | Collect II |
|----------|------|-------|------------|---------|-----------|------|-------|------------|---------|------------|
| 1        | HPV67| HR    | 308        | No      |           | HPV6  | LR    | 126        | No      |            |
| 2        | HPV66| HR    | 894        | No      |           | HPV65 | HR    | 734        | No      |            |
| 3        | HPV56| HR    | 854        | No      |           | HPV70 | HR    | 795        | CIN I   |            |
| 4        | HPV16| HR    | 148        | CIN II  | CIN III   | HPV16 | HR    | 168        | CIN II  | CIN III    |
| 5        | HPV31| HR    | 426        | No      |           | HPV16 | HR    | 355        | No      |            |
| 6        | HPV66| HR    | 590        | No      |           | HPV114| HR    | 690        | No      |            |
| 7        | HPV62| LR    | 1186       | No      |           | HPV62 | LR    | 1462       | No      |            |
| 8        | HPV16| HR    | 1023       | No      |           | HPV62 | HR    | 1004       | No      |            |
| 9        | HPV55| LR    | 811        | No      |           | HPV62 | HR    | 615        | No      |            |
| 10       | HPV70| HR    | 1825       | No      |           | HPV70 | HR    | 903        | CIN I   | CIN III    |
| 11       | HPV81| LR    | 624        | No      |           | HPV70 | HR    | 516        | No      |            |
| 12       | HPV83| LR    | 345        | No      |           | HPV70 | LR    | 441        | No      |            |
| 13       | HPV72| LR    | 658        | CIN I   |           | HPV70 | LR    | 712        | No      |            |
| 14       | HPV56| HR    | 177        | CIN I   |           | HPV59 | HR    | 218        | No      |            |
| 15       | HPV81| LR    | 296        | CIN I   |           | HPV81 | HR    | 213        | CIN I   |            |
| 16       | HPV66| HR    | 756        | CIN I   |           | HPV62 | HR    | 638        | CIN I   |            |
| 17       | HPV90| HR    | 560        | No      |           | HPV62 | HR    | 684        | No      |            |
| 18       | HPV56| HR    | 36         | No      |           | HPV62 | HR    | 49         | CIN I   |            |
| 19       | HPV31| LR    | 358        | No      |           | HPV62 | LR    | 320        | CIN I   |            |
| 20       | HPV62| LR    | 112        | CIN I   |           | HPV62 | LR    | 222        | No      |            |
| 21       | HPV26| LR    | 1120       | No      |           | HPV52 | LR    | 985        | No      |            |
| 22       | HPV54| LR    | 452        | No      |           | HPV52 | LR    | 319        | CIN I   |            |
| 23       | HPV56| HR    | –          | No      |           | HPV62 | LR    | –          | No      |            |
| 24       | HPV87| LR    | 682        | CIN I   |           | HPV62 | LR    | 616        | No      |            |
| 25       | HPV56| HR    | 876        | CIN I   |           | HPV56 | HR    | 753        | CIN I   | CIN III    |
| 26       | HPV   | neg   | –          | No      |           | HPV56 | LR    | 985        | No      |            |
| 27       | HPV11| LR    | 459        | No      |           | HPV26 | LR    | 465        | No      |            |
| 28       | HPV   | neg   | –          | No      |           | HPV11 | LR    | 576        | No      |            |
| 29       | HPV   | neg   | –          | No      |           | HPV11 | LR    | 878        | No      |            |
| 30       | HPV   | neg   | –          | No      |           | HPV18 | HR    | 693        | No      |            |
| 31       | HPV   | neg   | –          | No      |           | HPV70 | HR    | 1101       | No      |            |
| 32       | HPV   | neg   | –          | No      |           | HPV70 | HR    | 892        | CIN I   |            |
| 33       | HPV   | neg   | –          | No      |           | HPV70 | HR    | 1023       | No      |            |
| 34       | HPV   | neg   | –          | No      |           | HPV70 | LR    | 1012       | No      |            |
| 35       | HPV   | neg   | –          | No      |           | HPV70 | LR    | 616        | CIN I   |            |
| 36       | HPV   | neg   | –          | No      |           | HPV70 | LR    | 687        | No      |            |
| 37       | HPV   | neg   | –          | No      |           | HPV70 | LR    | 354        | No      |            |
| 38       | HPV   | neg   | –          | No      |           | HPV70 | LR    | 1044       | No      |            |
| 39       | HPV   | neg   | –          | No      |           | HPV74 | LR    | 287        | No      |            |
| 40       | HPV   | neg   | –          | No      |           | HPV   | neg   | –          | No      | 647        |

CIN I = cervical intraepithelial neoplasia low grade, CIN II = Cervical intraepithelial neoplasia moderate grade, CIN III = cervical intraepithelial neoplasia high grade to carcinoma in situ, HPV = human papilloma virus, HPV neg = HPV negative, HR = high-risk, LR = low-risk.
participants was 46 years. No association was observed between the presence of cervical lesions and age (P = .84), or between HPV presence in collected samples in both visits (P = .25/P = .63) (Table 3).

All 40 patients were diagnosed as HIV-positive, and in collection I, 34 (85%) were undergoing antiretroviral therapy (ART) and 6 (15%) had voluntarily abandoned the treatment for HIV control. At the second collection 32 patients (80%) were under treatment, and 8 (20%) had abandoned the antiretroviral therapy (Table 3).

Regarding the mean CD4 counts, in this study, the values were 635.8 cell/mm³ (SD = 320.9 cell/mm³ and median = 647.0 cell/mm³) and 644.5 cell/mm³ (SD = 391.2 cell/mm³ and median = 658.0 cell/mm³) in collections I and II, respectively (Table 3). No association was found between the CD4 count and the prevalence of cervical lesions in either visit (P = .15/P = .25). On the other hand, HIV viral load above 50 copies/mL was statistically associated with the occurrence of cervical lesions in the collection II samples (P = .045) (Table 3).

4. Discussion

It is well known that women infected with HIV are at increased risk of developing cervical cancer due to a greater risk of HPV infection and persistence as the result of immunosuppression. HIV-infected women also have a higher prevalence of a broad range of HPV genotypes as well as multiple concurrent infections.[23]

In this study, we found a high prevalence of HPV in HIV-positive women (73.5%). This result is in line with previous studies that found that HPV prevalence in HIV-infected women was in the range of 48% to 68% in Brazil.[23] Similar findings were observed in the United States, where the prevalence of HPV in HIV-infected women was in the range of 54% to 73%.[23,26] In European countries, the general prevalence of HPV in HIV-infected women is slightly lower, with estimates in the range of 44%.[27]

High-risk HPV subtypes were found in 57.5% of our patients’ samples. Similar results were described for European populations, in which high-risk HPVs were detected in 49.5% of HIV-infected women.[28] On the other hand, in South African populations, the prevalence of high-risk HPV in HIV-positive women varied from 60%[29] to 75%.[14]

The most frequent genotype in our study was HPV56, followed by the most prevalent type in non-HIV infected women, HPV16. Interestingly, Luque and co-workers[30] also determined that high-risk types other than HPV16 were most prevalent in a diverse population of HIV-positive women in Rochester, New York. In line with our findings, HPV56 was also the most prevalent type found in HIV-infected women in the Bahamas.[31] Several other studies also pointed to a higher prevalence of HPV56 in HIV-infected women, not only in Brazilian populations[32,33] but also in India.[23,24]

HPV16 and HPV56 were third and the fifth most frequent genotypes in patients with cervicitis and CIN I, respectively,[35] and in cases with multiple HPV infections, HPV16 and HPV56 had a higher risk of being present in CIN II lesions.[35] In our study, HIV patients co-infected with HPV56 and HPV16 had CIN II/II and CIN II/III, respectively.

In our study, we also observed a relatively low prevalence of HPV16 (15.3%), considering that it is the most prevalent type in non-HIV infected women and the most important high-risk HPV type. This result is supported by data indicating that HPV16 is often detected at low frequencies when compared to other types in HIV-seropositive women.[36] Some experts have hypothesized that HPV16 has better evolutionary ability to escape the effects of immune surveillance, while non-HPV16 genotypes are often better controlled by the immune response.[36,37] Consequently, in women with progressive weakening of the immune system, the immune control over non-HPV16 types may be lost, promoting the rise in the prevalence of types frequently targeted by a competent immune system.[37]

Our data also show a statistically significant association between HIV viral load and the occurrence of cervical lesions. This finding is corroborated by other studies, in which HIV viral load has been shown to significantly increase the risk of CIN development, especially because of its role in facilitating persistent HPV infection.[28,38] Furthermore, HIV viral load also affects the risk of cervical lesion recurrence.[28,39,40] and it is frequently found in patients with abnormal cytology.[41]
No association was observed between the CD4 count and the occurrence of cervical lesions. These data are supported by other studies that have indicated that the risk of CIN and the prevalence of SIL are not affected by the degree of immunosuppression.[42,43] However, abnormal cytological findings were reported to be frequent in women with CD4 counts lower than 200 cell/mm³.[27] In our study, the average CD4 count varied from 635.8 cell/mm³ in collection I to 644.5 cell/mm³ in collection II. Therefore, these data may explain why no positive association was found in our study. Importantly, nearly 83% of the women enrolled in this study were on ART. ART may lead to a reduction in the risk of high-grade squamous intraepithelial lesions and cervical cancer, but the prevalence of HPV infection in HIV-infected women remains high, even in individuals on effective ART.[44]

Considering this and the fact that some countries offer no effective cancer prevention programs, HIV-infected women are still at a greater risk of developing HPV-related malignancies, and strategies to define ideal cervical cancer prevention programs for these women urgently need to be defined.

5. Conclusion

HIV-infected women show a high prevalence of HPV infection, particularly by HPV56 and HPV16. Since HPV56 is not among the types included in the quadrivalent vaccine, we believe that monitoring patients infected with HPV56 could prevent cervical cancer and contribute to a better prognosis, especially in HIV/HPV co-infected patients with high HIV viral load.

Author contributions

Conceptualization: M. Calmon, P. Prozavazi, P. Rahal, R. Badial. Data curation: J. Cordeiro, P. Prozavazi, P. Rahal, R. Badial. Formal analysis: J. Cordeiro, R. Badial. Funding acquisition: C. Bonfim, P. Rahal. Investigation: B. Stuqui, C. Bonfim, M. Calmon, M. Dias, P. Melli, P. Rahal, R. Badial, S. Quintana. Methodology: B. Stuqui, C. Bonfim, M. Calmon, M. Dias, P. Prozavazi, P. Melli, R. Badial, S. Quintana. Project administration: P. Prozavazi, P. Rahal. Resources: P. Rahal. Supervision: P. Prozavazi, P. Rahal. Validation: P. Rahal, R. Badial. Visualization: R. Badial. Writing – original draft: R. Badial. Writing – review & editing: P. Prozavazi, P. Rahal, R. Badial, T. Rabachini.

References

[1] Morshed K, Polz-Gruszka D, Szymanski M, et al. Human papillomavirus (HPV) - structure, epidemiology and pathogenesis. Otolaryngol Pol 2014;68:213–9.
[2] Alemi M, Mohabatkar H, Behbahan M. In silico comparison of low- and high-risk human papillomavirus proteins. Appl Biochem Biotechnol 2014;172:188–95.
[3] Lu S, Cong X, Li M, et al. Distribution of high-risk human papillomavirus genotypes in HPV-infected women in Beijing, China. J Med Virol 2015;87:504–7.
[4] Meloni A, Pilia R, Campagna M, et al. Prevalence and molecular epidemiology of human papillomavirus infection in Italian women with cervical cytological abnormalities. J Public Health Res 2014;3:157.
[5] Haedecke J, Iftner T. Human papillomaviruses and cancer. Radiother Oncol 2013;108:397–402.
[6] Roos P, Orlando PA, Fagerstrom RM, et al. In North America, some ovarian cancers express the oncoproteins of preventable human papillo-

[7] Afrjelo M, Zheng ZM. E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78. MBio 2015;6:e02065–02014.
[8] Lin K, Lu X, Chen J, et al. E6-associated transcription patterns in human papilloma virus 16-positive cervical tissues. Oncol Lett 2015;9:478–82.
[9] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
[10] Cancer In. Estimativa 2016. Incidência do Câncer no Brasil. Rio de Janeiro. 15. Available at: https://www.cancer.org.br/sobre-o-cancer/ estimativa/.
[11] Bouler GA, Horvath CA, Berghmans S, et al. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiomarkers Prev 2008;17:810–7.
[12] Lima MD, Braz-Silva PH, Pereira SM, et al. Oral and cervical HPV infection in HIV-positive and HIV-negative women attending a sexual health clinic in Sao Paulo, Brazil. Int J Gynaecol Obstet 2014;126:33–6.
[13] Munro A, Codde J, Semmens J, et al. Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GP’s awareness and knowledge. Aust Fam Physician 2015;44:64–8.
[14] Adler DH, Wallace M, Bennie T, et al. Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa. Infect Dis Obstet Gynecol 2014;2014:498048.
[15] Bounimba LM, Hilali L, Mousaffi M, et al. Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women. BMC Public Health 2014;14:1320.
[16] Isola J, DeVries S, Chu L, et al. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival parafin-embedded tumor samples. Am J Pathol 1994;145:1301–8.
[17] Fussell Haws AL, He Q, Rady PL, et al. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004;122:87–93.
[18] Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463–7.
[19] Lee SH, Vigliotti VS, Vigliotti JS, et al. Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol 2009;9:3.
[20] Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990;215:403–10.
[21] Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41;4.
[22]Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002;12:656–68.
[23] Joshi S, Babu JM, Jayalakshmi D, et al. Human papillomavirus infection among human immunodeficiency virus-infected women in Maharasht, India. Vaccine 2014;32:1079–85.
[24] Araujo AC, Carvalho NO, Teixeira NC, et al. Incidence of cervical intraepithelial neoplasia in a cohort of HIV-infected women. Int J Gynaecol Obstet 2012;117:211–6.
[25] Brinkman JA, Jones WE, Gaffga AM, et al. Detection of human papillomavirus DNA in urine specimens from human immunodeficiency virus-positive women. J Clin Microbiol 2002;40:3153–61.
[26] Ellerbrock TV, Chiarison MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031–7.
[27] Garbuglia AR, Psellin P, Lapa D, et al. Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy. J Clin Virol 2012;54:141–6.
[28] Heard I, Cubie HA, Mesher D, et al. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2013;120:41–9.
[29] McDonald AC, Tergas AI, Kuhn L, et al. Distribution of human papillomavirus genotypes and related abnormalities of cervical cytologi-
al results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006;194:428–34.
[30] Damas DN, Blackman E, Butler R, et al. High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas. PLoS One 2014;9:e85429.
[31] Bruno A, Sarravalle K, Traversos AG, et al. [Genotype distribution of human papillomavirus in women from the state of Bahia, Brazil]. Rev Bras Ginecol Obstet 2014;36:416–22.
[33] Coser J, Boeira Tda R, Wolf JM, et al. Cervical human papillomavirus infection and persistence: a clinic-based study in the countryside from South Brazil. Braz J Infect Dis 2016;20:61–8.

[34] Mane A, Nirmalkar A, Rishud AR, et al. HPV genotype distribution in cervical intraepithelial neoplasia among HIV-infected women in Pune, India. PLoS One 2012;7:e38731.

[35] Xu H, Lin A, Shao X, et al. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget 2016;7:83775–83.

[36] Massad LS, Xie X, Burk RD, et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol 2016;214: 354 e 351-356.

[37] Zhang R, He YF, Chen M, et al. Diagnosis of 23 genotypes of human papillomaviruses for their physical statuses in cervical precancerous/cancerous lesions: a comparison of E2/E6E7 ratio-based vs. multiple E1-L1/E6E7 ratio-based detection techniques. J Transl Med 2014;12:282.

[38] Camargo M, Soto-De Leon SC, Munoz M, et al. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer 2014;14:451.

[39] Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008;111:1380–7.

[40] Frega A, Biamonti A, Maranghi L, et al. Follow-up of high-grade squamous intra-epithelial lesions (HSILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors. Anticancer Res 2006;26(4B):3167-70.

[41] Zeier MD, Botha MH, Engelbrecht S, et al. Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV. AIDS 2015;29:59–66.

[42] Lehtovirta P, Paavonen J, Heikinheimo O. Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS 2008;19:37–41.

[43] Madeddu G, Mameli G, Capobianco G, et al. HPV infection in HIV-positive females: the need for cervical cancer screening including HPV-DNA detection despite successful HAART. Eur Rev Med Pharmacol Sci 2014;18:1277–85.

[44] Palešky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS 2017;12:26–30.